Regeneron Pharmaceuticals has signed a $2.32bn research collaboration with Parabilis Medicines to develop therapeutic candidates leveraging the latter’s Helicon peptide platform, with an emphasis on ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--FogPharma®, a biopharmaceutical company pioneering a new class of precision medicines that could ultimately prove applicable to the vast majority of therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results